Disease · MONDO_0003005

macular retinal edema

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. macular retinal edema. Diseases, record MONDO_0003005. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003005

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: macular retinal edema; Open Targets
Open Targets ID: MONDO_0003005; Open Targets
Other names: macula lutea retinal edema, macula lutea retinal oedema, macular edema, retinal edema of macula lutea, retinal oedema of macula lutea; Open Targets
Disease Ontology: DOID:4449; Disease Ontology
NCI Thesaurus: C35468; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 44 drugs, from DailyMed and EMA Human Drugs; Open Targets

Drugs44

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RANIBIZUMAB	CHEMBL1201825	Antibody	Approval	DailyMed and EMA Human Drugs	68	59	57	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed and EMA Human Drugs	38	36	35	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Approval	DailyMed and EMA Human Drugs	43	28	27	Drugs and targets
FARICIMAB	CHEMBL4297750	Antibody	Approval	EMA Human Drugs	3	2	2	Drugs and targets
FLUOCINOLONE ACETONIDE	CHEMBL989	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	20	20	18	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 3	ClinicalTrials.gov	16	16	16	Drugs and targets
TRIAMCINOLONE	CHEMBL1451	Small molecule	Phase 3	ClinicalTrials.gov	7	7	6	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CONBERCEPT	CHEMBL2108313	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 44

See all 44 drugs

Targets42

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
VEGFA	Vascular endothelial growth factor A, long form	8	Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor	Approval	https://conductscience.org/library/genes/7422	Drugs and targets
PTGS2	Cyclooxygenase	5	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Phase 3	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	4	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5742	Drugs and targets
CA2	Carbonic anhydrase 2	2	Carbonic anhydrase II inhibitor	Phase 2/3	https://conductscience.org/library/genes/760	Drugs and targets
PGF	Placenta growth factor	2	Placenta growth factor inhibitor	Approval	https://conductscience.org/library/genes/5228	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/154	Drugs and targets
ANGPT2	Angiopoietin-2	1	Angiopoietin-2 inhibitor	Approval	https://conductscience.org/library/genes/285	Drugs and targets
CA1	Carbonic anhydrase 1	1	Carbonic anhydrase I inhibitor	Phase 2	https://conductscience.org/library/genes/759	Drugs and targets

1 to 10 of 42

See all 42 targets

Trials170

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05850520	A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)	Phase 3	892	2025-12-18	Macular Edema Secondary to Retinal Vein Occlusion	AFLIBERCEPT	Its record names the disease	ClinicalTrials.gov
NCT00379795	An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO	Not applicable	853	2012-01-13	Choroidal Neovascularization, Age-related Macular Degeneration	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04740931	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion	Phase 3	729	2024-01-18	Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion	FARICIMAB	Its record names the disease	ClinicalTrials.gov
NCT00105027	The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study	Phase 3	682	2011-01-19	Macular Edema, Cystoid, Retinal Vein Occlusion	TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT00168298	A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion	Phase 3	668	2009-08-26	Macular Edema, Retinal Vein Occlusion	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT01442064	An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)	Not applicable	608	2012-01-10	Macular Edema, Retinal Vein Occlusion	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00168324	A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion	Phase 3	599	2009-08-26	Macular Edema, Retinal Vein Occlusion	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT04592419	A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)	Phase 3	568	2024-06-06	Macular Edema, Retinal Vein Occlusion	TARCOCIMAB TEDROMER	Its record names the disease	ClinicalTrials.gov
NCT04740905	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion	Phase 3	553	2024-01-18	Macular Edema, Branch Retinal Vein Occlusion	FARICIMAB	Its record names the disease	ClinicalTrials.gov
NCT03810313	Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion	Phase 3	493	2022-08-08	Central Retinal Vein Occlusion	AFLIBERCEPT, BROLUCIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 170

See all 170 trials

Comparisons in its trials61

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Aflibercept vs Bevacizumab: deaths from any cause	1 of 180	1 of 182	362	NCT01969708	Trial comparisons
Aflibercept vs Bevacizumab: serious adverse events	14 of 180	14 of 182	362	NCT01969708	Trial comparisons
700 μg Dexamethasone vs Sham: serious adverse events	1 of 129	2 of 130	259	NCT01660802	Trial comparisons
Ranibizumab vs Dexamethasone: Rate of the Internal Ocular Pressure (IOP)	79 of 126	106 of 118	244	NCT01396057	Trial comparisons
Ranibizumab vs Dexamethasone: serious adverse events	7 of 126	9 of 118	244	NCT01396057	Trial comparisons
Ranibizumab vs Dexamethasone: Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline	94 of 124	105 of 119	243	NCT01396083	Trial comparisons
Ranibizumab vs Dexamethasone: serious adverse events	10 of 124	16 of 119	243	NCT01396083	Trial comparisons
Macular Laser Photocoagulation Treatment (Control) vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321): serious adverse events	10 of 92	13 of 91	183	NCT01521559	Trial comparisons
Macular Laser Photocoagulation Treatment (Control) vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321): Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF	24 of 90	48 of 91	181	NCT01521559	Trial comparisons
Ranibizumab vs Sham With Ranibizumab: Number of Participants Requiring Rescue Treatment at Month 1	0 of 117	0 of 60	177	NCT01846299	Trial comparisons

1 to 10 of 61

See all 61 comparisons in its trials

Papers from its trials98

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35256840	RESULT	1	PubMed
32041669	RESULT	1	PubMed
28492910	RESULT	1	PubMed
27654837	RESULT	1	PubMed
26802783	RESULT	1	PubMed
25439614	RESULT	1	PubMed
25390730	RESULT	1	PubMed
24084497	RESULT	1	PubMed
23298885	RESULT	1	PubMed
22999634	RESULT	1	PubMed

1 to 10 of 98

See all 98 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003005

GET https://conductscience.org/api/diseases/v1/MONDO_0003005/drugs?page=2

API reference For AI assistants